



Client: Ascension Peptides

Certified: 06/02/2026

This Certificate of Analysis certifies that the sample listed herein was tested by Kovera Labs using validated analytical methods and was found to meet the stated specifications at the time of analysis.

SAMPLE INFORMATION

Product	Tesamorelin	Form	Lyophilized powder
Batch	32-05260628	Labeled Qty	5 mg
Mol. Formula	C221H366N72O67S	CAS Number	901758-09-6
Cap Color	Red	Crimp Color	Silver

TEST RESULTS


	REFERENCE STANDARD	RESULT
Purity	(>98%)	99.703%
Net Content	(~5mg)	5.56 mg
Identity Confirmation (LC-MS)	(Tesamorelin)	Tesamorelin
Endotoxin Safety Screen	(≤0.5 EU/mL)	PASS
Microbial Sterility Screen	(No Growth)	No Growth

HEAVY METAL SCREENING

Analyte	Result	Status
Arsenic (As)	Negative	
Cadmium (Cd)	Negative	
Lead (Pb)	Negative	
Mercury (Hg)	Negative	

CHROMATOGRAM

Method: RP-HPLC | Column: C18 | Detection: DAD @ 214 nm



Lemar Arghandinal
Lab Director



koveralabs.com/verify

Report#: KVR-2026-E24151
Access Code: Y29XOK2

CLIENT & SAMPLE INFORMATION

Client	Ascension Peptides	Analysis Date	06/02/2026
Product Name	Tesamorelin	Strength	5 mg
Lot / Batch	32-05260628	Condition	Lyophilized

This Certificate of Analysis certifies that the sample listed herein was tested for bacterial endotoxin using a kinetic chromogenic LAL assay in accordance with USP <85> Bacterial Endotoxins Test.

TEST METHODOLOGY

Test Performed	Quantitative Bacterial Endotoxin Test	Compendial Ref	USP <85>
Assay Type	Kinetic Turbidimetric	Detection λ	660 nm
Detection Range	0.01 - 1.0 EU/mL	Endotoxin Std	E. coli O111:B4
Dilution Vol	2.0 mL	Matrix	LAL Reagent Water

QUANTITATIVE RESULTS

Parameter	Result
Endotoxin Level	< 0.20 EU/mL
Acceptance Limit	≤ 0.5 EU/mL
Sample CV (%)	N/A
Spike CV (%)	N/A
Spike Recovery (%)	N/A
Final Determination	PASS

CONTROLS

Control	Expected	Observed	Status
Positive Control	Detectable	As expected	Pass
Negative Control	No signal	As expected	Pass

INTERPRETATION

Endotoxin content was quantitatively determined using a kinetic chromogenic LAL assay in accordance with USP <85>. Result reported as below quantitation threshold. The measured endotoxin level meets the specified acceptance criteria. The sample passes the endotoxin limit test.

AUTHORIZATION

REVIEWED BY
Lemar Arghandiwal
Lab Director





CLIENT & SAMPLE INFORMATION

Client	Ascension Peptides	Analysis Date	June 03, 2026
Product Name	Tesamorelin	Strength	5 mg
Lot / Batch	32-05260628	Condition	Lyophilized

ICP-MS metals analysis performed using EPA-referenced methods; results evaluated against internal acceptance criteria.

TEST METHODOLOGY

Test Performed	Elemental Impurities Analysis	Instrument	ICP-MS
Sample Prep	HNO ₃ / H ₂ O ₂ matrix	Calibration	Multi-element standard curve
Internal Std	Sc, Ge, In, Bi	Material Type	Raw Material (Research Use)

ELEMENTAL IMPURITIES RESULTS

Element	Result (ppm)	Acceptance Limit (ppm)	Status
Pb Lead	< 0.5	≤ 10	PASS
As Arsenic	< 0.15	≤ 1.5	PASS
Cd Cadmium	< 0.05	≤ 0.5	PASS
Hg Mercury	< 0.3	≤ 3	PASS

METHOD SUITABILITY (SPIKE RECOVERY)

Element	Spike Level	Recovery	Criteria
Pb Lead	5 ppm	98%	70–150%
As Arsenic	0.75 ppm	102%	70–150%
Cd Cadmium	0.25 ppm	95%	70–150%
Hg Mercury	1.5 ppm	91%	70–150%

Spike recovery confirms method suitability for the sample matrix.

INTERPRETATION

Elemental impurities were determined using ICP-MS with EPA-referenced analytical methods. All tested elements (Pb, As, Cd, Hg) are below the stated acceptance limits. Spike recovery values fall within acceptable ranges, confirming method suitability. The sample meets the stated acceptance criteria for elemental impurities.

QUALITY CONTROL

Method Blank: Pass CCV: Pass Duplicate RPD: < 20%

AUTHORIZATION

REVIEWED BY

Lemar Arghandiwal
Lab Director



CLIENT & SAMPLE INFORMATION

Client	Ascension Peptides	Sample Name	Tesamorelin
Lot Number	32-05260628	Date Received	06/02/2026
Date Certified	06/02/2026	Sample Matrix	Lyophilized powder

TEST METHODOLOGY
RAPID STERILITY SCREENING METHOD

Sample is reconstituted and incubated in growth media under controlled conditions. Cultures are monitored for microbial growth over the incubation period. This rapid screening method provides preliminary sterility assessment and is suitable for quality control purposes. For regulatory compliance, full compendial sterility testing may be required.

TEST RESULTS

TEST PARAMETER	SPECIFICATION	RESULT	STATUS
Bacteria (Aerobic/Anaerobic)	No Growth	No Growth	PASS
Fungi / Yeast	Not Detected	Not Detected	PASS
TEST METHOD Rapid Sterility	INCUBATION PERIOD 2 days	TEMPERATURE 30-35C	

FINAL DETERMINATION

STERILITY SCREEN RESULT
SAMPLE PASSES STERILITY SCREEN

No microbial growth detected during incubation period

